Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pedi...
Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-ter...
Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for th...
ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, announced that it has entered into a col...
Genomics leader relocates to an expanded footprint in Sunnyvale New location enables customer continuity and provides increased innovation space to driv...
Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy m...
Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, and a global CRDMO operating from five sites across India ...
TetraScience, the Scientific Data and AI company, announced a collaboration with Thermo Fisher Scientific Inc., the world leader in ser...
Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic application...
Revvity, Inc. announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by ma...
Accelerated pathway: Integrated cell line development, process development, analytics, GMP drug substance, plus drug product support through quali...
Sharp Sterile Manufacturing has announced a $28 million expansion of its site in Lee, Massachusetts. The enhanced state-of-the-art facility will st...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for...
MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated...
© 2026 Biopharma Boardroom. All Rights Reserved.
